Cells 2012, 1(4), 1246-1260; doi:10.3390/cells1041246
Neovascularization in Tissue Engineering
1
Division of Cardiac Surgery, McGill University Health Center, McGill University, 687 Pine Avenue West, Suite S8.73b, Montreal H3A-1A1, Quebec, Canada
2
Division of Surgical Research, McGill University Health Center, McGill University, 687 Pine Avenue West, Suite S8.73b, Montreal H3A-1A1, Quebec, Canada
*
Author to whom correspondence should be addressed.
Received: 31 August 2012 / Revised: 8 November 2012 / Accepted: 5 December 2012 / Published: 11 December 2012
(This article belongs to the Special Issue Tissue and Organ Regeneration)
View Full-Text
|
Download PDF [205 KB, uploaded 11 December 2012]
Abstract
A prerequisite for successful tissue engineering is adequate vascularization that would allow tissue engineering constructs to survive and grow. Angiogenic growth factors, alone and in combination, have been used to achieve this, and gene therapy has been used as a tool to enable sustained release of these angiogenic proteins. Cell-based therapy using endothelial cells and their precursors presents an alternative approach to tackling this challenge. These studies have occurred on a background of advancements in scaffold design and assays for assessing neovascularization. Finally, several studies have already attempted to translate research in neovascularization to clinical use in the blossoming field of therapeutic angiogenesis. View Full-Text
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Share & Cite This Article
MDPI and ACS Style
Chung, J.C.-Y.; Shum-Tim, D. Neovascularization in Tissue Engineering. Cells 2012, 1, 1246-1260.